Križevci vs Solin - Second NL

Few would have predicted the narrative arc that brings Križevci and Solin together at the home ground on October 3, 2026, and the underdog storyline only adds to the Second NL occasion. How smooth can you be when receiving the ball, how quickly can you move from the back foot, hips open, face forward and find quality with the pass.

Both camps will view the Second NL meeting at the home ground as an opportunity to put a marker down, regardless of where they currently stand. The hosts have been steady if unspectacular, W in their last five reflecting a win rate of 50%. Solin have blown hot and cold, D across their last five and a season win rate of 25%. The contrast in attacking output — 1.75 versus 1 goals per game — adds an extra layer of intrigue. But the Reds are still unsure about Bologna's asking price for the defender, who turned 28 in June and has less than 12 months to run on his contract at the Serie A side.

The tactical battle could prove decisive. Križevci may lean on their home advantage to dictate the tempo, but Solin have shown they can be dangerous when allowed to play on their own terms. But this approach also takes something that is almost anonymous in football - time.

Game-changers are scattered across both line-ups, and the contest may well be decided by which side's match-winners deliver on the day. The battle in midfield, where both sides look to control tempo, could prove the decisive arena. Chelsea have confirmed the signing of former Manchester United striker Danny Welbeck from Brighton.

Without the market to lean on, the contest feels genuinely open — and the outcome may come down to which side handles the occasion better. The signals point towards a stalemate, with the two sides closely matched across form and standings. A 2-2 draw is easy to envisage. The ramifications of this result could ripple through the Second NL standings for weeks to come, regardless of who comes out on top. The team currently most likely to win the 2026 WNBA Finals according to Opta.